Inhibition of PCSK9 in high-risk patients. Less c-LDL is more

被引：0

作者：

Diaz, Rafael ^{[1
]}

机构：

[1] ICR, Bv Orono 450,S2000DSR, Rosario, Santa Fe, Argentina

来源：

REVISTA DE LA FEDERACION ARGENTINA DE CARDIOLOGIA | 2019年 / 48卷 / 01期

关键词：

Inhibition of PCSK9; Risk of vascular events; LDL cholesterol; EFFICACY; THERAPY; SAFETY;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3 / 5

页数：3

共 6 条

[1] Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, Christopher P.
Blazing, Michael A.
Giugliano, Robert P.
McCagg, Amy
White, Jennifer A.
Theroux, Pierre
Darius, Harald
Lewis, Basil S.
Ophuis, Ton Oude
Jukema, J. Wouter
De Ferrari, Gaetano M.
Ruzyllo, Witold
De Lucca, Paul
Im, KyungAh
Bohula, Erin A.
Reist, Craig
Wiviott, Stephen D.
Tershakovec, Andrew M.
Musliner, Thomas A.
Braunwald, Eugene
Califf, Robert M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (25) : 2387 - 2397
[2] Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
Fulcher, Jordan
O'Connell, Rachel
Voysey, Merryn
Emberson, Jonathan
Blackwell, Lisa
Mihaylova, Borislava
Simes, John
Collins, Rory
Kirby, Adrienne
Colhoun, Helen
Braunwald, Eugene
La Rosa, John
Pedersen, T. R.
Tonkin, Andrew
Davis, Barry
Sleight, Peter
Franzosi, Maria Grazia
Baigent, Colin
Keech, Anthony
de Lemos, J.
Blazing, M.
Murphy, S.
Downs, J. R.
Gotto, A.
Clearfield, M.
Holdaas, H.
Gordon, D.
Koren, M.
Dahloef, B.
Poulter, N.
Sever, P.
Knopp, R. H.
Fellstroem, B.
Holdaas, H.
Jardine, A.
Schmieder, R.
Zannad, F.
Goldbourt, U.
Kaplinsky, E.
Colhoun, H. M.
Betteridge, D. J.
Durrington, P. N.
Hitman, G. A.
Fuller, J.
Neil, A.
Wanner, C.
Krane, V.
Sacks, F.
Moye, L.
Pfeffer, M.
[J]. LANCET, 2015, 385 (9976) : 1397 - 1405
[3] Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
Giugliano, Robert P.
Sabatine, Marc S.
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 65 (24) : 2638 - 2651
[4] Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
Ridker, P. M.
Revkin, J.
Amarenco, P.
Brunell, R.
Curto, M.
Civeira, F.
Flather, M.
Glynn, R. J.
Gregoire, J.
Jukema, J. W.
Karpov, Y.
Kastelein, J. J. P.
Koenig, W.
Lorenzatti, A.
Manga, P.
Masiukiewicz, U.
Miller, M.
Mosterd, A.
Murin, J.
Nicolau, J. C.
Nissen, S.
Ponikowski, P.
Santos, R. D.
Schwartz, P. F.
Soran, H.
White, H.
Wright, R. S.
Vrablik, M.
Yunis, C.
Shear, C. L.
Tardif, J. -C.
Conde, Diego
Colquhoun, David
Missault, Luc
Gregoire, Jean
Gao, Runlin
Urina, Miguel
Solar, Miroslav
Jensen, Henrik Kjaerulf
Grobbee, Diederick
Savolainen, Markku
Schiele, Francois
Montalescot, Gilles
Edes, Istvan
Blake, Gavin
Lotan, Chaim
Maggioni, Aldo
Savonitto, Stefano
Lee, Cheol Whan
Leiva Pons, Jose Luis
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16) : 1527 - 1539
[5] Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI [10.4997/JRCPE.2017.212, 10.1056/NEJMoa1615664]
[6] Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G.
Steg, P. G.
Szarek, M.
Bhatt, D. L.
Bittner, V. A.
Diaz, R.
Edelberg, J. M.
Goodman, S. G.
Hanotin, C.
Harrington, R. A.
Jukema, J. W.
Lecorps, G.
Mahaffey, K. W.
Moryusef, A.
Pordy, R.
Quintero, K.
Roe, M. T.
Sasiela, W. J.
Tamby, J. -F.
Tricoci, P.
White, H. D.
Zeiher, A. M.
Aylward, Philip E.
Drexel, Heinz
Sinnaeve, Peter
Dilic, Mirza
Lopes, Renato D.
Gotcheva, Nina N.
Goodman, Shaun G.
Prieto, Juan-Carlos
Yong, Huo
Lopez-Jaramillo, Patricio
Pecin, Ivan
Reiner, Zeljko
Ostadal, Petr
Poulsen, Steen Hvitfeldt
Viigimaa, Margus
Nieminen, Markku S.
Danchin, Nicolas
Chumburidze, Vakhtang
Marx, Nikolaus
Liberopoulos, Evangelos
Montenegro Valdovinos, Pablo Carlos
Tse, Hung-Fat
Kiss, Robert Gabor
Xavier, Denis
Zahger, Doron
Valgimigli, Marco
Kimura, Takeshi
Kim, Hyo Soo
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (22) : 2097 - 2107

← 1 →